Antibiotics Market Size, Share & Growth Trend Analysis Report By Type of Drug Class, Target Disease Indication, Type of Therapy, Route of Administration (2026 - 2035)

Antibiotics Market Size

The antibiotics market size, valued at USD 37 billion in 2025, is projected to reach USD 37 billion in 2026 and USD 41 billion by 2035, representing a CAGR of 1.2% during the forecast period 2026 to 2035.

Antibiotics Market Report: Key Takeaways

• In terms of type of drug class, the other drug class segment secures >60% of the overall revenue share of the global market.
• Antibiotics has two types of therapies, such as monotherapies and combination therapies. Of which, monotherapy holds the majority of the share (~80%) in the current year.

• With regards to target disease indication, urinary tract infections hold the largest antibiotics market share (~30%) in 2025, followed by other bacterial infections.
• Based on route of administration, the oral route of administration captures the majority of the market share. Notably, the market for intravenous segment will grow at a relatively faster CAGR.

• In terms of geographical analysis, Europe is likely to hold majority of the market share, and this trend is likely to remain same in the coming years.

Antibiotics Market Overview

Bacterial infections are known to be one of the leading causes of deaths worldwide. In fact, infections caused by bacteria are responsible for every one out of eight deaths, globally. This can be attributed to the fact that majority of the pathogenic bacteria have developed resistance against the commonly prescribed therapies. In addition, as per the Centers for Disease Control and Prevention (CDC), the annual healthcare cost associated with treatment of infections caused by six multi drug resistant bacteria is estimated to be more than USD 4.6 billion in the US.

Antibiotics (chemical substances derived from the biological sources or produced chemically) are extensively being used for the prevention / treatment of various bacterial infections. Over the past few years, a number of novel broad spectrum antibiotics (antibiotics that provide therapeutic effects against a wide range of bacteria) and narrow spectrum antibiotics (antibiotics that provide therapeutic effects against specific bacterial strains only), targeting a myriad of bacterial infections (in alphabetical order), including anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis, have received approval from various regulatory authorities, globally.

However, the antibiotic drug development is currently fraught with several challenges, including emergence of multi drug resistant bacteria, antibiotics shortage (particularly penicillin shortage and amoxicillin shortage) and concerns related to safety and efficacy of these therapies. In order to address the aforementioned concerns, several industry stakeholders have been actively leading the efforts for research and development of effective and safe antibiotics. In addition, over the years, several regulatory organizations, including the World Health Organization (WHO), CDC and United States Food and Drug Administration (USFDA) have undertaken various initiatives to not only promote the correct usage of antibiotics but also support the players engaged in this industry.

Driven by the continuous efforts of both industry and non-industry players and growing concerns associated with antimicrobial resistance, the global antibiotics industry is likely to witness significant growth during the forecast period.

Antibiotics Market Trends

• Use of AI in Antibiotic Discovery: A number of companies and academic researchers are using AI models and deep learning based drug screening algorithms to discover novel antibiotics. Genentech, Phare Bio and MIT are some active players in this space.
• Big Pharma Moving Out of Antibiotics Development: A number of big pharma companies discontinued their antibiotic drug development programs, mainly driven by limited financial reward, difficulty in identifying truly novel molecules, and limited lifespan of antibiotics owing to development of antimicrobial resistance.
• Drugs Being Repurposed as Antibiotics: In July 2025, a group of researchers at MIT, identified Halicin as having potent antibacterial action against a few multidrug-resistant bacterial strains. The drug was originally developed as a JNK inhibitor targeting diabetes and its repurposed application was identified using a deep learning based algorithm. Emory University has also repurposed fendiline, approved as a treatment for heart arrythmia, as having an antibacterial action against Acinetobacter baumannii.

Antibiotics Market Share Insights

Market Share by Drug Class

• The global antibiotics market is categorized into Aminoglycosides, Cephalosporins, Fluoroquinolones, Macrolides, Oxazolidinones, Penicillin, Sulphonamides, Tetracyclines and Other Drug Classes.
• Aminoglycoside accounts for the largest market share, in terms of revenues.
• Several aminoglycoside antibiotics, such as gentamicin, amikacin, tobramycin, and streptomycin, have been approved for the treatment of severe bacterial infections, including those caused by Gram-negative organisms. The continued clinical adoption of these agents underscores their critical role in addressing antimicrobial resistance and hospital-acquired infections.

Market Share by Key Geographical Regions

• This segment highlights the distribution of antibiotics market size across various geographies, such as North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world.
• According to our projections, North America is likely to capture the majority of the market share in the current year, and this trend is unlikely to change in the future.
• The market in North America is driven by high antibiotic consumption, and advanced healthcare infrastructure.

Key Market Insights

Need for Novel Antibiotics Targeting Multi Drug Resistant Bacteria

Over the years, due to overuse of antibiotics, bacterial strains have developed resistance to most of the commercially available antibiotics, a phenomenon known as antibiotic resistance / antimicrobial resistance. Notably, in November 2021, the World Health Organization (WHO) declared antimicrobial resistance as one of the top ten threats for the global public health standards.

In order to address the aforementioned challenge, pharmaceutical companies are currently evaluating various novel antibiotics. These novel antibiotics belong to previously unexplored drug classes that can target new pathways to inhibit bacterial growth. In addition, some of these therapies are being evaluated to overcome the challenges of cross resistance (commonly observed in currently available antibiotics).

Clinical Trial Analysis: More than 1,720 Trials are Evaluating Various Antibiotics Drug Classes to Fight Antimicrobial Resistance

Over the years, companies involved in the development of antibiotics have made significant efforts to conduct clinical trials for evaluating the efficacy of antibiotics, for the treatment of various infectious diseases, including urinary tract infection, pulmonary infection, respiratory tract infection, sexually transmitted disease and skin infection. Currently, over 1,720 trials are registered across different geographical regions to evaluate various antibiotics drug classes. Of these trials, majority (696) were registered in North America. Within this region, the maximum number of trials were / are being conducted in the US (630). Additionally, majority of the patients (14,21,308) were observed to be enrolled in trials conducted in North America, accounting for about 20% of the overall enrollment. It is worth noting that Pfizer, GlaxoSmithKline, Merck, Melinta Therapeutics and Janssen emerged to be the most active players in terms of number of trial conducted in antibiotics market domain.

Impact of COVID-19 on the Antibiotics Industry

It is worth highlighting that a significant surge has been observed in the use of antibiotics, since 2020. This can be attributed to the fact that various antibiotic generics, namely azithromycin, ceftriaxone, moxifloxacin and meropenem, were used extensively in the initial phase of the pandemic. However, the COVID-19 pandemic caused the disruption of the supply chain of antibiotics. As a result, there is antibiotics shortage due to increasing demand for antibiotics.  Hence, in order to address the increasing demand as well as overcome the aforementioned supply chain-related disruption, a number of developers based in North America and Europe either expanded their facilities or established new facilities for the manufacturing of antibiotics.

Market Analysis: Global Antibiotics Market Size

The global antibiotics market is estimated to be worth USD 37 billion in 2026. Driven by the increasing need for novel antibiotics, along with growing development pipeline and encouraging clinical trial results, the antibiotics market is anticipated to grow at a CAGR of 1.2% in the forecast period. It is worth highlighting that majority of the current market share is captured by players based in North America in the forecast period.

Leading Antibiotics Companies

Examples of the key players in this domain (the complete list of players is available in the full report) include ABAC Therapeutics, Bayer, Biocidium Biopharmaceuticals, Blacksmith Medicines, Bristol Myers Squibb, Crestone, Daiichi Sankyo, Debiopharm, Fedora Pharmaceuticals, Fujisawa Pharmaceutical, GlaxoSmithKline, Helperby Therapeutics, Madam Therapeutics, Melinta Therapeutics, Meiji Seika Pharma, MicuRx Pharmaceuticals, Merck, Pfizer, Qpex Biopharma, RedHill Biopharma, Selmod, Sequella, Sinovent, Spero Therapeutics and Wockhardt.

Antibiotics Market Segmentation Insights

Key Report Attributes

Frequently Asked Questions